Precipio, Inc. (PRPO) Research

Precipio, Inc., based in New Haven, Connecticut, functions as a healthcare solutions provider within the United States. The company delivers a range of diagnostic products, reagents, and services, specifically offering diagnostic testing for blood cancers. Its advanced offerings include IV-Cell, a unique cell culture media capable of simultaneously growing four types of hematopoietic cell lineages, and HemeScreen, a comprehensive collection of genetic diagnostic panels. Precipio also develops COVID-19 antibody tests. A notable proprietary innovation is ICE-COLD PCR, a patented technology designed to boost the sensitivity of molecular tests, with kits for this technology also sold to biopharmaceutical customers. Additionally, Precipio, Inc. collaborates with academic institutions dedicated to cancer research, diagnosis, and therapy.

Market snapshot

Symbol
PRPO
Price
$22.45
Day change
+0.40%
Market cap
$40.1M
P/E ratio
-43.42x
52-week range
10.516-33.63
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Next earnings
in 1 month

Peer companies

  • Apimeds Pharmaceuticals US, Inc (APUS)
  • Intensity Therapeutics, Inc. (INTS)
  • Iterum Therapeutics plc (ITRM)
  • Longduoduo Company Limited (LDDD)
  • Milestone Scientific Inc. (MLSS)
  • Modular Medical, Inc. (MODD)
  • Pluri Inc. (PLUR)
  • Precision Optics Corporation, Inc. (POCI)

Recent insider activity

  • SANDBERG RICHARD A — S-Sale (900 shares) on 2026-05-21
  • SANDBERG RICHARD A — S-Sale (2034 shares) on 2026-05-20
  • SANDBERG RICHARD A — S-Sale (600 shares) on 2026-05-19
  • SANDBERG RICHARD A — S-Sale (500 shares) on 2026-05-20
  • Valauri Christina Rizopoulos — A-Award (93 shares) on 2026-04-15

Open Precipio, Inc. (PRPO) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.